+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 65Years
All Genders
ID02115295

Phase II Study of Cladribine, Idarubicin, Cytarabine, and Venetoclax for Treating Adults with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Myeloid Blast Phase Chronic Myeloid Leukemia

Led by M.D. Anderson Cancer Center · Updated on 2026-05-20

508

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well a combination of chemotherapy drugscladribine, idarubicin, cytarabine, and venetoclaxwork in treating patients with acute myeloid leukemia AML, high-risk myelodysplastic syndrome MDS, or myeloid blast phase chronic myeloid leukemia CML. This phase II trial aims to determine the complete response rate and overall response rate, assess survival outcomes, duration of response, safety, and tolerability of the treatment. The study also explores molecular biomarkers and disease characteristics related to treatment outcomes. Treatment includes an induction phase where patients receive intravenous cladribine and cytarabine for 5 days, and idarubicin for 3 days. Patients with untreated AML and MDS also take venetoclax orally for 7 days. Those with specific FLT3 mutations may receive additional oral targeted drugs, midostaurin or gilteritinib, for varying days. This induction cycle repeats every 28 days for up to 2 cycles if tolerated. The consolidation phase follows with shorter intravenous drug administration over 3 days and oral venetoclax for 7 days, repeated every 28 days for up to 5 cycles. Targeted drugs continue as applicable during consolidation. Participants undergo regular follow-up visits every 6 to 12 months after completing study treatment. Throughout the trial, researchers monitor treatment response, survival, adverse effects, and molecular disease markers. The main measurement is the complete response rate within 12 months. Other assessments include overall survival, event-free survival, and toxicity incidence. The trial lasts up to one year for outcome evaluations, with ongoing long-term follow-up.

CONDITIONS

Brief Title

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Research Team

T

Tapan Kadia

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here